Shanghai Junshi Biosciences Co., Ltd.
Símbolo: 1877.HK
HKSE
12.6
HKDPrecio de mercado actual
-5.6777
Ratio PER
0.0426
Ratio PEG
27.42B
Capitalización MRK
- 0.00%
Rendimiento DIV
Shanghai Junshi Biosciences Co., Ltd. (1877-HK) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3778.1 | 5996.9 | 3504.6 | ||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 341.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 483.2 | 517.7 | 1834.8 | ||||||||
balance-sheet.row.inventory | 0 | 538.1 | 599 | 484.6 | ||||||||
balance-sheet.row.other-current-assets | 0 | 744.4 | 91.3 | 7.7 | ||||||||
balance-sheet.row.total-current-assets | 0 | 5549.8 | 7204.9 | 5831.7 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 4253.3 | 3572 | 3421.3 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.long-term-investments | 0 | 1133.1 | 1402.8 | 1123.4 | ||||||||
balance-sheet.row.tax-assets | 0 | 103.4 | 228.4 | 88.5 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 188.4 | 57.6 | 533.9 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 5812.6 | 5371.4 | 5219 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.account-payables | 0 | 247.3 | 281.6 | 196.2 | ||||||||
balance-sheet.row.short-term-debt | 0 | 575.3 | 435.4 | 45.1 | ||||||||
balance-sheet.row.tax-payables | 0 | 59.4 | 35.2 | 80.9 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 1213.2 | 886.2 | 583.1 | ||||||||
Deferred Revenue Non Current | 0 | 181.1 | 121.6 | 118.8 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7.5 | 1057.2 | 1775.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1547.1 | 1007.8 | 701.9 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 53.4 | 90.2 | 127.6 | ||||||||
balance-sheet.row.total-liab | 0 | 4022.3 | 2782 | 2718.5 | ||||||||
balance-sheet.row.preferred-stock | 0 | 0.3 | 68.4 | 0 | ||||||||
balance-sheet.row.common-stock | 0 | 985.7 | 982.9 | 910.8 | ||||||||
balance-sheet.row.retained-earnings | 0 | -9040.8 | -6776.6 | -4388.6 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -142.1 | -68.4 | 0.2 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 15367.7 | 15295.2 | 11438.5 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7170.8 | 9501.4 | 7960.9 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 169.4 | 292.8 | 371.3 | ||||||||
balance-sheet.row.total-equity | 0 | 7340.2 | 9794.3 | 8332.2 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 1133.1 | 1402.8 | 1464.9 | ||||||||
balance-sheet.row.total-debt | 0 | 1788.6 | 1321.6 | 628.2 | ||||||||
balance-sheet.row.net-debt | 0 | -1989.6 | -4675.4 | -2876.4 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -2675.2 | -592.6 | -1669.5 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 293.7 | 262.6 | 151.4 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -173.8 | -5.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 91.9 | 192.8 | 30.7 | |||||||
cash-flows.row.change-in-working-capital | 0 | 687.2 | -318.8 | -13.1 | |||||||
cash-flows.row.account-receivables | 0 | 1229.7 | -770.6 | -482.2 | |||||||
cash-flows.row.inventory | 0 | -136.4 | -154.8 | -167 | |||||||
cash-flows.row.account-payables | 0 | -1229.7 | 770.6 | 482.2 | |||||||
cash-flows.row.other-working-capital | 0 | 823.6 | -163.9 | 153.9 | |||||||
cash-flows.row.other-non-cash-items | 0 | -172.9 | -12 | 7.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.acquisitions-net | 0 | -93.8 | -440.1 | 2.9 | |||||||
cash-flows.row.purchases-of-investments | 0 | -8.5 | -1169.6 | -245.2 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 565.3 | 70.1 | |||||||
cash-flows.row.other-investing-activites | 0 | 28.6 | 49.7 | 66.8 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -467.6 | -1881 | -698 | |||||||
cash-flows.row.debt-repayment | 0 | -113.4 | -793.3 | -401.4 | |||||||
cash-flows.row.common-stock-issued | 0 | 3812.3 | 2150.1 | 4846.9 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 19.2 | 16.7 | 43.2 | |||||||
cash-flows.row.dividends-paid | 0 | -19.2 | -16.7 | -43.2 | |||||||
cash-flows.row.other-financing-activites | 0 | 944.2 | 1308.9 | -32 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 4643 | 2665.7 | 4413.5 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 92.3 | -23.2 | -45.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 2492.3 | 119.6 | 2171 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 5996.9 | 3504.6 | 3385 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3504.6 | 3385 | 1214 | |||||||
cash-flows.row.operating-cash-flow | 0 | -1775.3 | -641.9 | -1498.8 | |||||||
cash-flows.row.capital-expenditure | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.free-cash-flow | 0 | -2169.3 | -1528.1 | -2091.5 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1502.5 | 1453.5 | 4024.8 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 667.3 | 526.3 | 1258.2 | ||||||||
income-statement-row.row.gross-profit | 0 | 835.3 | 927.2 | 2766.7 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.operating-expenses | 0 | 3287.3 | 3644.2 | 3359.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 3954.6 | 4170.4 | 4617.5 | ||||||||
income-statement-row.row.interest-income | 0 | 99.4 | 61 | 31 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 303.2 | 293.7 | 262.6 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -2476 | -2671.6 | -685.3 | ||||||||
income-statement-row.row.income-before-tax | 0 | -2489.9 | -2675.2 | -592.6 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 44 | -93.1 | 135.5 | ||||||||
income-statement-row.row.net-income | 0 | -2281.6 | -2582.1 | -728.2 |
Preguntas frecuentes
Cuánto es Shanghai Junshi Biosciences Co., Ltd. (1877.HK) activos totales?
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) los activos totales son 11362464000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son N/A.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es -0.024.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -2.642.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es -3.152.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -3.231.
¿Qué es Shanghai Junshi Biosciences Co., Ltd. (1877.HK) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -2281624000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 1788567000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 3287276000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 0.000.